Biotech Values

[DewDiligence]

Moreover, about 50% of PKI’s business pertains to environmental testing rather than biotech. So the proportion of PKI’s business that’s exposed to ILMN-related woes is about 25% — the non-service-contract half of the biotech half.

All told, the PKI sell-off looks like an overreaction in a skittish stock market. We’ll know for sure when PKI reports its earnings on Nov 3.